Literature DB >> 25904153

A meta-analytic assessment of the risk of chronic kidney disease in patients with chronic hepatitis C virus infection.

H Park1, A Adeyemi1, L Henry2, M Stepanova2, Z Younossi3,4.   

Abstract

Epidemiological studies have reported conflicting results regarding hepatitis C virus (HCV) infection and the risk of chronic kidney disease (CKD). We systematically reviewed the literature to determine the risk of developing CKD in HCV-infected individuals compared to uninfected individuals. MEDLINE and PUBMED were searched to identify observational studies that had reported an association between HCV and CKD or end-stage renal disease (ESRD) through January 2015. Quantitative estimates [hazard ratio (HR) or odds ratio (OR)] and their 95% confidence intervals (CI) were extracted from each study. A random-effects meta-analysis was performed. Fourteen studies evaluating the risk of developing CKD/ESRD in HCV-infected individuals (n = 336,227) compared to uninfected controls (n = 2,665,631) were identified- nine cohort studies and five cross-sectional studies. The summary estimate indicated that individuals with HCV had a 23% greater risk of presenting with CKD compared to uninfected individuals (risk ratio = 1.23; 95% CI: 1.12-1.34). Results were similar by study type, for cohorts (HR = 1.26; 95% CI: 1.12-1.40) and cross-sectional studies (OR = 1.21; 95% CI: 1.09-1.32). Country-stratified analysis demonstrated a significantly increased risk between HCV and CKD in the Taiwanese subgroup (risk ratio = 1.28; 95% CI: 1.12-1.34) and the US subgroup (risk ratio = 1.17; 95% CI: 1.01-1.32). Egger regression revealed no evidence of publication bias. HCV infection is associated with a greater risk of developing and progression of CKD compared to uninfected controls.
© 2015 John Wiley & Sons Ltd.

Entities:  

Keywords:  chronic kidney disease; hepatitis C virus

Mesh:

Year:  2015        PMID: 25904153     DOI: 10.1111/jvh.12413

Source DB:  PubMed          Journal:  J Viral Hepat        ISSN: 1352-0504            Impact factor:   3.728


  22 in total

1.  High rate of acute kidney injury in patients with chronic kidney disease and hepatitis C virus genotype 4 treated with direct-acting antiviral agents.

Authors:  Ahmed Yahia Elmowafy; Hanzada Mohamed El Maghrabi; Mohamed Elsayed Mashaly; Khaled Farouk Eldahshan; Lionel Rostaing; Mohamed Adel Bakr
Journal:  Int Urol Nephrol       Date:  2019-10-14       Impact factor: 2.370

2.  Treatment of HCV in Renal Disease: Subtle Management Considerations in the Era of Direct-acting Antivirals.

Authors:  Yuval A Patel; Andrew J Muir
Journal:  Curr Hepatol Rep       Date:  2016-11-05

Review 3.  A Pharmacology Perspective of Simultaneous Tuberculosis and Hepatitis C Treatment.

Authors:  Russell R Kempker; Wael A Alghamdi; Mohammad H Al-Shaer; Gena Burch; Charles A Peloquin
Journal:  Antimicrob Agents Chemother       Date:  2019-10-07       Impact factor: 5.191

Review 4.  Hepatitis C Virus Infection Increases the Risk of Developing Chronic Kidney Disease: A Systematic Review and Meta-Analysis.

Authors:  Fabrizio Fabrizi; Simona Verdesca; Piergiorgio Messa; Paul Martin
Journal:  Dig Dis Sci       Date:  2015-07-21       Impact factor: 3.199

Review 5.  Hepatitis C Virus Infection in Chronic Kidney Disease.

Authors:  Marco Ladino; Fernando Pedraza; David Roth
Journal:  J Am Soc Nephrol       Date:  2016-04-19       Impact factor: 10.121

Review 6.  Hepatitis C Virus Infection in the Older Patient.

Authors:  Michael Reid; Jennifer C Price; Phyllis C Tien
Journal:  Infect Dis Clin North Am       Date:  2017-12       Impact factor: 5.982

7.  Incidence and Progression of Chronic Kidney Disease After Hepatitis C Seroconversion: Results from ERCHIVES.

Authors:  Shari S Rogal; Peng Yan; David Rimland; Vincent Lo Re; Hind Al-Rowais; Linda Fried; Adeel A Butt
Journal:  Dig Dis Sci       Date:  2015-11-02       Impact factor: 3.199

8.  The Impact of Direct-Acting Antiviral Therapy on End-Stage Liver Disease Among Individuals with Chronic Hepatitis C and Substance Use Disorders.

Authors:  Haesuk Park; Xinyi Jiang; Hyun Jin Song; Vincent Lo Re; Lindsey M Childs-Kean; Wei-Hsuan Lo-Ciganic; Robert L Cook; David R Nelson
Journal:  Hepatology       Date:  2021-07-01       Impact factor: 17.425

9.  Tubular cell damage may be the earliest sign of renal extrahepatic manifestation caused by Hepatitis C.

Authors:  Kati Kaartinen; Sauli Vuoti; Eero Honkanen; Eliisa Löyttyniemi; Ravinder Singh; Martti Färkkilä
Journal:  PLoS One       Date:  2021-05-07       Impact factor: 3.240

10.  Pharmacokinetics of elbasvir and grazoprevir in subjects with end-stage renal disease or severe renal impairment.

Authors:  Luzelena Caro; Larissa Wenning; Hwa-Ping Feng; Zifang Guo; Lihong Du; Pratik Bhagunde; Christine Fandozzi; Deborah Panebianco; William L Marshall; Joan R Butterton; Marian Iwamoto; Wendy W Yeh
Journal:  Eur J Clin Pharmacol       Date:  2019-01-25       Impact factor: 3.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.